Management of Menorrhagia in CKD Patients

First-Line Pharmacologic Approach

• For CKD stage 3 patients, the dose of tranexamic acid should be reduced to 50% of standard (500-750mg three times daily) to prevent neurotoxicity, as recommended by the guideline society 1
• For CKD stage 4 patients, the dose of tranexamic acid should be reduced to 25% of standard (250-500mg twice daily) or avoided entirely due to high neurotoxicity risk, as recommended by the guideline society 1

Alternative Hormonal Therapies

• Intrauterine levonorgestrel 20 mcg/day can produce a significant reduction in menstrual blood loss, though 44% of patients may develop amenorrhea, and requires no dose adjustment for renal function, as noted by the guideline society 2

Critical Medications to Avoid

• NSAIDs should never be prescribed in CKD patients due to nephrotoxicity risk, causing acute kidney injury and worsening heart failure, as warned by the Kidney International 3 and the guideline society 4

Management of Anemia Secondary to Menorrhagia

• Intravenous iron should be administered to CKD patients with iron deficiency from menorrhagia to improve functional status and quality of life, regardless of anemia status, as recommended by the guideline society 1
• Correcting iron deficiency may improve platelet function even without changing platelet count, as noted by the guideline society 2

Monitoring Requirements

• Monitor renal function (eGFR, serum creatinine) at baseline, 1-2 weeks after initiating tranexamic acid, then every 3-6 months, as recommended by the guideline society 1
• Assess iron status at baseline and periodically during treatment, as recommended by the guideline society 1 and 2

Surgical Considerations When Medical Management Fails

• When surgical procedures are necessary, use iso-osmolar contrast agents and minimize contrast volume to prevent contrast-induced nephropathy, as recommended by the guideline society 1

Critical Pitfalls to Avoid

• Never prescribe NSAIDs for menorrhagia in CKD patients, regardless of symptom severity, due to nephrotoxicity and cardiovascular risks, as warned by the Kidney International 3 and the guideline society 4
• Do not assume menorrhagia is the sole cause of anemia—investigate other CKD-related causes, including iron deficiency and erythropoietin deficiency, as recommended by the guideline society 1 and 2